Royalty Pharma Plc · NASDAQ:RPRX
Royalty Pharma — Investor Presentation (November 2024)
6 slides from Royalty Pharma's investor presentation, November 2024
Slide 1: Royalty Pharma
ROYALTY PHARMA
Slide 2: Royalty acquisition: Geron's Rytelo FDA approved for LR-MDS
royalty acquisition Geron’s Rytelo is FDA approved for lower-risk myelodysplastic syndromes with transfusion dependent anemia November 2024
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or
Slide 4: Rytelo – uniquely positioned to address unmet need in LR-MDS
Rytelo – uniquely positioned to address unmet need in LR-MDS 1 2 3 FDA approved for LR-MDS Treatment landscape for LR- Attractive commercial with TD anemia MDS needs innovation opportunity for Rytelo Geron’s Rytelo is an FDA approved (June Limited treatment options for patients ~13,200 U.S. patients
Slide 5: Rytelo – uniquely positioned to address unmet need in LR-MDS
Rytelo – uniquely positioned to address unmet need in LR-MDS ’s Rytleo U.S. consensus sales projections(3) ($ in millions) • Acquired a synthetic royalty on Geron’s Rytelo for LR-MDS anemia ▪ $125 million upfront payment ▪ Entitled to a royalty of 7.75% on annual U.S. net sales up to $500m, 3% betwe
Slide 6: Rytelo received favorable placement in the NCCN guidelines
Rytelo – uniquely positioned to address unmet need in LR-MDS Rytelo received favorable placement in the NCCN guidelines as a 2nd line treatment • Treatment landscape for LR-MDS, a progressive form of blood cancer, has seen limited innovation LR-MDS with symptomatic anemia ▪ Symptomatic anemia and re
Royalty Pharma — Investor Presentation (November 2024) on 6ix